

Chemicals/Finland, February 20, 2023 Company update

### Demand picks up towards year's end

Exel's Q4 figures missed estimates as demand was still softer than expected. H1'23 results are likely to remain modest relative to the high comparison period, but guidance indicates at least some improvement for H2'23.

#### Heady growth continued in H1'22, but H2'22 was slower

Exel's Q4 revenue landed at EUR 31m vs the EUR 36m/35m Evli/cons. estimates. Destocking, after a period of high demand following the initial shock of the pandemic, has been an issue lately and is expected to continue in H1'23. Equipment and other industries, the third largest customer group, was particularly soft relative to our estimates but there seems to have been nothing special going on apart from the destocking issues as well as normal cyclicality. The soft top line left adj. EBIT at EUR 0.9m vs the EUR 2.4m/2.0m Evli/cons. estimates.

#### H1'23 will still be soft; guidance suggests better H2'23

Exel sees improvement from Q2 in orders as well as EBIT; top line is to remain flat this year, while EBIT has ground from which to gain. The Runcorn cuts should produce EUR 1.6m in annual savings. Inflation hasn't been a big issue for Exel and raw materials are stabilizing. Wind power should again grow, according to Exel, at a 15% y/y pace from H2'23. Wind power was Exel's largest customer in 2019-20 and continued to grow at a CAGR of 16.5% in FY '20-21, however its revenue fell by EUR 5.3m last year and was overtaken by Buildings and infrastructure already in 2021. Exel got its challenges in the US sorted out last year, but the relative softness in the three largest customer groups left its adj. EBIT for the year at EUR 8.0m (we consider it a modest level). We note the four smaller industries together grew by 19% last year, although this was mostly attributable to Transportation as it enjoyed pent-up demand after the pandemic and received initial orders for a new aerospace application.

#### Valuation is not challenging if growth returns in H2'23

Exel is valued 9.5x EV/EBIT on our FY '23 estimates, which we consider a neutral level. The multiple is not very low, however we estimate an EBIT margin of 6.3% for the year whereas the company should still be on track towards its long-term 10% target (it reached almost 9% in FY '20). For FY '24 we estimate 7% growth and 7.5% EBIT margin, which would translate to an EV/EBIT of 7.5x. Our new TP is EUR 5.8 (6.5); our rating is BUY.



Share price, EUR (Last trading day's closing price)	5.10 5.8
Target price, EUR	3.0
Latest change in recommendation	20-Jul-21
Latest report on company	04-Nov-22
Research paid by issuer:	YES
No. of shares outstanding, '000's	11,897
No. of shares fully diluted, '000's	11,897
Market cap, EURm	61
Free float, %	100.0
Exchange rate EUR/USD	1.07
Reuters code	EXL1V.HE
Bloomberg code	EXL1V FH
Average daily volume, EURm	0.1
Next interim report	02-May-23
Web site	www.exelcomposites.com
Analyst	Joonas Ilvonen
E-mail	joonas.ilvonen@evli.com
Telephone	+358 44 430 9071

■ BUY □ HOLD ■ SELL

KEY FIGU	RES									
	Sales EURm	EBIT EURm	EBIT %	FCF EURm	EPS EUR	P/E (x)	EV/Sales (x)	EV/EBIT (x)	FCF yield %	DPS EUR
2021	134.4	3.7	2.8%	-6.2	0.14	57.0	1.0	34.9	-6.5	0.20
2022	137.0	3.0	2.2%	9.4	0.18	30.1	0.7	31.4	14.6	0.20
2023E	140.5	8.9	6.3%	6.7	0.41	12.6	0.6	9.7	11.0	0.25
2024E	150.3	11.3	7.5%	5.7	0.47	10.8	0.6	7.4	9.4	0.30
2025E	157.9	13.4	8.5%	8.4	0.70	7.3	0.5	5.9	13.9	0.32
Market cap	o, EURm		61 G	earing 2023E,	0/0		77.6 CAGR	EPS 2022-2	5, %	57.3
Net debt 2	023E, EURm		26 P	rice/book 2023	BE		1.8 CAGR	sales 2022-	25, %	4.8
Enterprise	value, EURm		86 D	ividend yield 2	2023E, %			15.3		
Total asset	s 2023E, EURn	n	112 Ta	ax rate 2023E,	0/0			10.0		
Goodwill 2	.023E, EURm		13 E	quity ratio 202	23E, %		29.3 PEG, F	P/E 23/CAGR		0.5



Chemicals/Finland, February 20, 2023 Company update

## Estimates and peer group multiples

Exel Composites	2019	2020	2021	Q1'22	Q2'22	Q3'22	Q4'22	2022	Q1'23e	Q2'23e	Q3'23e	Q4'23e	2023e
Buildings and infrastructure	23.5	23.5	32.9	7.7	8.9	7.8	8.1	32.5	6.8	7.7	8.4	9.0	31.9
Equipment and other industrie	18.6	19.5	23.4	7.4	5.9	5.6	4.3	23.1	6.5	6.0	5.7	4.4	22.6
Wind power	23.6	28.1	32.1	6.8	6.5	8.0	5.5	26.8	5.9	5.7	8.6	6.2	26.4
Machinery and electrical	14.4	15.5	17.6	4.3	5.3	5.0	5.2	19.7	4.4	5.5	5.1	5.5	20.5
Transportation	13.1	10.2	10.2	3.1	7.2	3.7	3.3	17.4	3.8	8.0	5.1	4.5	21.4
Defense	2.3	5.3	8.7	2.1	1.6	2.0	1.9	7.5	2.2	1.6	2.1	2.0	7.9
Telecommunications	8.2	6.5	9.5	2.8	2.8	1.7	2.6	10.0	2.7	2.8	1.8	2.7	10.0
Revenue	103.8	108.6	134.4	34.2	38.1	33.8	31.0	137.0	32.2	37.3	36.6	34.4	140.5
y/y change, %	7 %	5 %	24 %	10 %	14 %	1 %	-15 %	2 %	-6 %	-2 %	8 %	11%	3 %
Adjusted EBIT	7.2	9.7	6.0	2.2	3.1	1.8	0.9	8.0	1.2	2.7	2.8	2.2	8.9
EBIT	5.1	9.4	3.7	0.0	3.0	1.7	-1.7	3.0					
-margin, %	6.9 %	8.9 %	4.5 %	6.4 %	8.2 %	5.4 %	3.0 %	5.9 %	3.7 %	7.2 %	7.6 %	6.4 %	6.3 %
-margin (reported), %	4.9 %	8.7 %	2.8 %	0.1 %	7.9 %	5.0 %	-5.5 %	2.2 %					

Source: Evli Research

	MCAP		EV/EBITDA			EV/EBIT			EBIT-%	
EXEL COMPOSITES PEER GROUP	MEUR	22	23	24	22	23	24	22	23	24
Hexagon Composites	655			40.2x				-8.0 %	-7.2 %	-3.1 %
Hexcel	5760	19.0x	18.8x	15.6x	31.6x	28.4x	22.1x	11.4 %	13.5 %	15.7 %
Avient	3597	8.0x	10.3x	9.3x	11.6x	16.5x	13.8x	12.0 %	9.6 %	10.9 %
SGL Carbon	1071	5.8x	7.7x	6.8x	9.1x	12.5x	10.8x	9.7 %	8.5 %	9.3 %
TPI Composites	513	17.4x	18.9x	8.3x			16.6x	-2.8 %	-0.5 %	2.7 %
Peer Group Average	2319	12.6x	13.9x	16.0x	17.4x	19.1x	15.8x	4.4 %	4.8 %	7.1 %
Peer Group Median	1071	12.7x	14.5x	9.3x	11.6x	16.5x	15.2x	9.7 %	8.5 %	9.3 %
Exel Composites (Evli est.)	61	9.3x	5.8x	4.1x	31.4x	9.7x	7.4x	2.2 %	6.3 %	7.5 %
Exel Composites prem./disc. to peer median	7	-27 %	-60 %	-56 %	170 %	-41 %	-51 %	-77 %	-25 %	-20 %

Source FactSet, Evli Research

Chemicals/Finland, February 20, 2023 Company update

VALUATION RESULTS	BASE CASE DETAILS	VALUATION ASSUMPTIONS	ASSUMPTIONS FOR WACC	
Current share price	5.10 PV of Free Cash Flow	67 Long-term growth, %	1.5 Risk-free interest rate, %	2.25
DCF share value	9.75 PV of Horizon value	79 WACC, %	8.5 Market risk premium, %	5.8
Share price potential, %	91.1 Unconsolidated equity	0 Spread, %	0.5 Debt risk premium, %	3.3
Maximum value	10.7 Marketable securities	17 Minimum WACC, %	8.0 Equity beta coefficient	1.00
Minimum value	8.9 Debt - dividend	-47 Maximum WACC, %	9.0 Target debt ratio, %	10
Horizon value, %	54.3 Value of stock	116 Nr of shares, Mn	11.9 Effective tax rate, %	21

DCF valuation, EURm	2022	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	Horizon
Net sales	137	141	150	158	163	166	169	173	176	180	182	185
Sales growth, %	2.0	2.6	7.0	5.0	3.0	2.0	2.0	2.0	2.0	2.0	1.5	1.5
Operating income (EBIT)	3	9	11	13	16	17	19	20	20	21	21	21
Operating income margin, %	2.2	6.3	7.5	8.5	10.0	10.5	11.0	11.5	11.5	11.5	11.5	11.5
+ Depreciation+amort.	7	6	6	6	5	5	5	4	4	4	4	
EBITDA	10	15	17	19	22	22	23	24	25	25	25	
- Paid taxes	-1	-3	-4	-6	-7	-7	-8	-8	-8	-8	-9	
- Change in NWC	3	-1	-1	-1	-1	0	0	-1	-1	-1	0	
NWC / Sales, %	10.3	10.4	10.7	10.9	11.1	11.1	11.2	11.3	11.3	11.4	11.5	
+ Change in other liabs	0	0	0	0	0	0	0	0	0	0	0	
- Operative CAPEX	-3	-3	-4	-4	-4	-4	-4	-4	-4	-4	-4	
opCAPEX / Sales, %	2.4	2.5	2.9	2.8	2.7	2.5	2.5	2.5	2.5	2.5	2.4	
- Acquisitions	0	0	0	0	0	0	0	0	0	0	0	
+ Divestments	0	0	0	0	0	0	0	0	0	0	0	
- Other items	0	0	0	0	0	0	0	0	0	0	0	
= FCFF	9	7	8	9	10	11	11	12	12	12	12	178
= Discounted FCFF		7	7	7	8	7	7	7	6	6	5	79
			-		-	-		-	-	-		
= DFCF min WACC		7	7	7	8	7	7	7	6	6	6	89
= DFCF max WACC		7	7	7	8	7	7	7	6	6	5	71

Chemicals/Finland, February 20, 2023 Company update

#### INTERIM FIGURES

EVLI ESTIMATES, EURm	2022Q1	2022Q2	2022Q3	2022Q4	2022	2023Q1E	2023Q2E	2023Q3E	2023Q4E	2023E	2024E	2025E
· · · · · · · · · · · · · · · · · · ·	34.2	38.1	33.8	31.0	137.0	32.2	37.3	36.6	34.4	140.5		157.9
Net sales											150.3	
EBITDA (QL)	1.8	4.8	3.6	0.0	10.1	2.7	4.2	4.3	3.7	14.8	17.2	19.0
EBITDA margin (%)	5.2	12.5	10.5	0.0	7.4	8.3	11.2	11.7	10.7	10.5	11.5	12.0
EBIT	0.0	3.0	1.7	-1.7	3.0	1.2	2.7	2.8	2.2	8.9	11.3	13.4
EBIT margin (%)	0.1	7.9	5.0	-5.5	2.2	3.7	7.2	7.7	6.4	6.3	7.5	8.5
Net financial items	0.5	1.9	1.6	-3.4	0.6	-0.2	-0.2	-0.2	-0.2	-0.8	-1.9	0.6
Pre-tax profit	0.5	4.9	3.3	-5.1	3.6	1.0	2.5	2.6	2.0	8.1	9.4	14.0
Tax	-0.5	-1.0	-1.2	1.2	-1.5	-0.4	-1.0	-1.1	-0.8	-3.3	-3.8	-5.7
Tax rate (%)	104.4	20.0	35.6	24.3	40.4	40.4	40.4	40.4	40.4	40.4	40.4	40.4
Net profit	0.0	3.9	2.1	-3.9	2.1	0.6	1.5	1.5	1.2	4.8	5.6	8.4
EPS	0.00	0.33	0.18	-0.33	0.18	0.05	0.13	0.13	0.10	0.41	0.47	0.70
EPS adjusted (diluted no. of shares)	0.00	0.33	0.18	-0.33	0.18	0.05	0.13	0.13	0.10	0.41	0.47	0.70
Dividend per share	0.00	0.00	0.00	0.00	0.20	0.00	0.00	0.00	0.00	0.25	0.30	0.32
SALES, EURm												
Exel Composites	34.2	38.1	33.8	31.0	137.0	32.2	37.3	36.6	34.4	140.5	150.3	157.9
Total	34.2	38.1	33.8	31.0	137.0	32.2	37.3	36.6	34.4	140.5	150.3	157.9
SALES GROWTH, Y/Y %												
Exel Composites	10.3	13.5	1.2	-15.1	2.0	-5.7	-2.0	8.3	11.0	2.6	7.0	5.0
<u>Total</u>	10.3	13.5	1.2	-15.1	2.0	-5.7	-2.0	8.3	11.0	2.6	7.0	5.0
EBIT, EURm												
Exel Composites	0.0	3.0	1.7	-1.7	3.0	1.2	2.7	2.8	2.2	8.9	11.3	13.4
Total	0.0	3.0	1.7	-1.7	3.0	1.2	2.7	2.8	2.2	8.9	11.3	13.4
EBIT margin, %												
Exel Composites	0.1	7.9	5.0	-5.5	2.2	3.7	7.2	7.7	6.4	6.3	7.5	8.5
Total	0.1	7.9	5.0	-5.5	2.2	3.7	7.2	7.7	6.4	6.3	7.5	8.5

Chemicals/Finland, February 20, 2023 Company update

INCOME STATEMENT, EURm	2018	2019	2020	2021	2022	2023E	2024E	2025E
Sales	96.6	103.8	108.6	134.4	137.0	140.5	150.3	157.9
Sales growth (%)	11.9	7.5	4.6	23.7	2.0	2.6	7.0	5.0
EBITDA	7.7	10.7	15.3	11.9	10.1	14.8	17.2	19.0
EBITDA margin (%)	8.0	10.3	14.1	8.9	7.4	10.5	11.5	12.0
Depreciation	-5.5	-5.6	-5.8	-8.2	-7.1	-5.9	-6.0	-5.6
EBITA	2.2	5.1	9.4	3.7	3.0	8.9	11.3	13.4
Goodwill amortization / writedown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	2.2	5.1	9.4	3.7	3.0	8.9	11.3	13.4
EBIT margin (%)	2.3	4.9	8.7	2.8	2.2	6.3	7.5	8.5
Reported EBIT	2.2	5.1	9.4	3.7	3.0	8.9	11.3	13.4
EBIT margin (reported) (%)	2.3	4.9	8.7	2.8	2.2	6.3	7.5	8.5
Net financials	-0.5	-1.2	-2.3	0.4	0.6	-0.8	-1.9	0.6
Pre-tax profit	1.7	3.9	7.1	4.2	3.6	8.1	9.4	14.0
Taxes	-1.3	-1.5	-1.7	-2.5	-1.5	-3.3	-3.8	-5.7
Minority shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net profit	0.4	2.4	5.4	1.7	2.1	4.8	5.6	8.4
Cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Non-cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BALANCE SHEET, EURm								
Assets								
Fixed assets	21	23	30	34	31	28	27	25
Goodwill	13	13	13	13	13	13	13	13
Right of use assets	5	5	3	3	2	2	2	3
Inventory	15	17	16	24	23	24	26	27
Receivables	20	20	21	26	24	25	27	28
Liquid funds	5	7	12	16	17	18	19	20
Total assets	79	85	97	118	113	112	115	118
Liabilities								
Shareholder's equity	26	26	29	31	30	33	35	40
Minority interest	0	0	0	0	0	0	0	0
Convertibles	0	0	0	0	0	0	0	0
Lease liabilities	3	4	2	2	1	2	2	3
Deferred taxes	0	0	0	0	1	1	1	1
Interest bearing debt	30	32	40	50	46	41	39	35
Non-interest bearing current liabilities	18	21	24	32	26	27	29	30
Other interest-free debt	2	2	2	3	9	9	9	9
Total liabilities	79	85	97	118	113	112	115	118
CASH FLOW, EURm								
+ EBITDA	8	11	15	12	10	15	17	19
- Net financial items	0	-1	-2	0	1	-1	-2	1
- Taxes	-2	-2	-2	-3	-1	-3	-4	-6
- Increase in Net Working Capital	-4	1	3	-5	3	-1	-1	-1
+/- Other	0	0	0	0	0	0	0	0
= Cash flow from operations	1	8	13	5	13	10	10	13
- Capex	-10	-8	-13	-11	-3	-4	-4	-4
- Acquisitions	0	0	0	0	0	0	0	0
+ Divestments	0	0	0	0	0	0	0	0
= Free cash flow	-9	1	0	-6	9	7	6	8
+/- New issues/buybacks	0	0	-1	3	-1	0	0	0
- Paid dividend	-4	-2	-2	-2	-2	-2	-3	-4
+/- Other	9	3	7	9	-5	-4	-1	-4

Chemicals/Finland, February 20, 2023 Company update

78 29 107 104 11 5 4 2 26 1.0 10.0 21.0 21.0 12.9	88 30 118 109 15 9 7 5 29 1.1 7.7	94 36 131 134 12 4 4 2 31	64 30 94 137 10 3 4 2 30	61 26 86 141 15 9 8 5 33	61 23 83 150 17 11 9 6	61 18 79 158 19 13 14 8
107 104 11 5 4 2 26 1.0 10.0 21.0 21.0	118 109 15 9 7 5 29 1.1 7.7 12.5	131 134 12 4 4 2 31	94 137 10 3 4 2 30	86 141 15 9 8 5 33	83 150 17 11 9	79 158 19 13 14
104 11 5 4 2 26 1.0 10.0 21.0 21.0	109 15 9 7 5 29 1.1 7.7 12.5	134 12 4 4 2 31	137 10 3 4 2 30	141 15 9 8 5 33	150 17 11 9 6	158 19 13 14
11 5 4 2 26 1.0 10.0 21.0 21.0	15 9 7 5 29 1.1 7.7 12.5	12 4 4 2 31	10 3 4 2 30	15 9 8 5 33	17 11 9 6	19 13 14 8
1.0 10.0 21.0 21.0	9 7 5 29 1.1 7.7 12.5	4 4 2 31	3 4 2 30	9 8 5 33	11 9 6	13 14 8
1.0 10.0 21.0 21.0	7 5 29 1.1 7.7 12.5	4 2 31	4 2 30	8 5 33	9 6	14 8
2 26 1.0 10.0 21.0 21.0	5 29 1.1 7.7 12.5	2 31 1.0	2 30	5 33	6	8
1.0 10.0 21.0 21.0	1.1 7.7 12.5	1.0	30	33		
1.0 10.0 21.0 21.0	1.1 7.7 12.5	1.0				
1.0 10.0 21.0 21.0	1.1 7.7 12.5	1.0				
10.0 21.0 21.0	7.7 12.5		0.7	0.0		
10.0 21.0 21.0	7.7 12.5				0.6	0.5
21.0 21.0	12.5		9.3	5.8	4.8	4.1
21.0		34.9	31.4	9.7	7.4	5.9
	12.5	34.9	31.4	9.7	7.4	5.9
12.5	8.8	27.2	7.4	8.5	8.3	6.1
32.5	52.9	-26.0	10.2	11.7	10.5	9.1
110.9	179.1	-15.3	6.8	9.1	10.6	7.2
						7.3
						1.5
						4.6
						6.5
						10.3
						1.7
0.0	0.0	0.0	0.0	14.3	12.3	8.3
						11,897
						11,897
						0.70
						1.08
						0.71
						3.39
						0.32
						45.6
	2.7		3.9	4.9	5.9	6.3
0.9	0.6	-6.5	14.6	11.0	9.4	13.9
9.2	19.5	5.5	7.0	15.3	16.4	22.0
8.6	14.4	5.1	4.0	10.0	11.8	17.6
16.3	14.9	17.8	17.1	17.1	17.1	17.1
19.2	19.2	19.6	17.8	17.8	17.7	17.7
20.2	22.0	23.8	19.1	19.1	19.1	19.1
14.1	11.2	12.7	10.3	10.4	10.7	10.9
		8.2		2.5	2.9	2.8
7.3	11.9	8.2	2.4			2.8
						0.5
						0.9
						0.6
30.8	29.7	26.5	26.9	29.3	30.8	34.2
110.2	104.7	115.9	98.1	77.6	64.2	44.5
	8.6 16.3 19.2 20.2 14.1 7.3 7.3 0.3 2.7 0.4	3.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11,897 11,897 11,897 11,897 0.20 0.45 0.70 1.12 0.06 0.04 2.21 2.41 0.18 0.20 89.2 44.3 2.7 2.7 0.9 0.6  9.2 19.5 8.6 14.4  16.3 14.9 19.2 19.2 20.2 22.0 14.1 11.2 7.3 11.9 7.3 11.9 7.3 11.9 0.3 0.1 2.7 2.0 0.4 0.5	3.0 3.1 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	3.0         3.1         3.0         2.1           0.0         0.0         0.0         0.0           0.0         0.0         0.0         0.0           0.0         0.0         0.0         0.0           0.0         0.0         0.0         0.0           0.0         0.0         0.0         0.0           11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897           11,897         11,897         11,897         10,897           0.06         0.04         -0.52         0.79           2.1         2.41         2.62         2.56           0.18         0.20         0.20         0.20           2.7         2.7         2.5 <td>3.0         3.1         3.0         2.1         1.8           0.0         0.0         0.0         0.0         6.4           0.0         0.0         0.0         0.0         10.6           0.0         0.0         0.0         0.0         14.2           0.0         0.0         0.0         0.0         2.1           0.0         0.0         0.0         0.0         2.1           0.0         0.0         0.0         0.0         2.1           0.0         0.0         0.0         0.0         2.1           0.0         0.0         0.0         0.0         2.1           0.0         0.0         0.0         0.0         14.3           11,897         11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897         11,897           11,897         11,499         1.14         0.18</td> <td>3.0         3.1         3.0         2.1         1.8         1.7           0.0         0.0         0.0         0.0         6.4         5.3           0.0         0.0         0.0         0.0         10.6         8.1           0.0         0.0         0.0         0.0         14.2         16.1           0.0         0.0         0.0         0.0         2.1         1.9           0.0         0.0         0.0         0.0         14.2         16.1           0.0         0.0         0.0         0.0         2.1         1.9           0.0         0.0         0.0         0.0         14.3         12.3           11,897         11,897         11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897         11,897         11,897           11,897         12,90</td>	3.0         3.1         3.0         2.1         1.8           0.0         0.0         0.0         0.0         6.4           0.0         0.0         0.0         0.0         10.6           0.0         0.0         0.0         0.0         14.2           0.0         0.0         0.0         0.0         2.1           0.0         0.0         0.0         0.0         2.1           0.0         0.0         0.0         0.0         2.1           0.0         0.0         0.0         0.0         2.1           0.0         0.0         0.0         0.0         2.1           0.0         0.0         0.0         0.0         14.3           11,897         11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897         11,897           11,897         11,499         1.14         0.18	3.0         3.1         3.0         2.1         1.8         1.7           0.0         0.0         0.0         0.0         6.4         5.3           0.0         0.0         0.0         0.0         10.6         8.1           0.0         0.0         0.0         0.0         14.2         16.1           0.0         0.0         0.0         0.0         2.1         1.9           0.0         0.0         0.0         0.0         14.2         16.1           0.0         0.0         0.0         0.0         2.1         1.9           0.0         0.0         0.0         0.0         14.3         12.3           11,897         11,897         11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897         11,897         11,897           11,897         11,897         11,897         11,897         11,897         11,897           11,897         12,90

#### **EVLI EQUITY RESEARCH**

## **EXEL COMPOSITES**

Chemicals/Finland, February 20, 2023 Company update

COMPANY DESCRIPTION: Exel Composites manufactures composites profiles for various demanding, mainly industrial end-use, applications. Exel's customer base includes companies operating in industries such as wind energy, transportation and telecommunications. Exel Composites is one of the largest manufacturers of pultruded composites profiles globally and currently operates eight manufacturing plants on three continents.

INVESTMENT CASE: Our positive view is based on good long-term composites demand outlook, coupled with the fact that Exel Composites' current manufacturing footprint could support annual revenue in the EUR 150m ballpark i.e. there's still plenty of room to improve delivery volumes. Exel's rather high fixed cost base translates to meaningful operating leverage, and thus higher revenues should lead to improving operating margins. The company is also progressing well with its cost savings program. Operating profit could further significantly improve if good execution continues. Recently the wind energy sector has provided great lift for volumes; other attractive applications include e.g. transportation industry profiles.

OWNERSHIP STRUCTURE	SHARES	EURm	0/0
Sijoitusrahasto Taaleritehdas Mikro Markka	800,000	4.080	6.7%
OP-Finland Small Firms Fund	590,119	3.010	5.0%
Ilmarinen Mutual Pension Insurance	496,547	2.532	4.2%
Op-Suomi Mikroyhtiöt -Erikoissijoitusrahasto	420,000	2.142	3.5%
Phoebus Fund	370,000	1.887	3.1%
Säästöpankki Pienyhtiöt	288,710	1.472	2.4%
Nelimarkka Heikki Antero	213,545	1.089	1.8%
Veritas Pension Insurance Company Ltd.	207,479	1.058	1.7%
Säästöpankki Kotimaa	132,680	0.677	1.1%
Sumato Oy	131,821	0.672	1.1%
Ten largest	3,650,901	18.620	31%
Residual	8,245,942	42.054	69%
Total	11,896,843	60.674	100%

EARNINGS CALENDAR	
May 02, 2023	Q1 report
August 18, 2023	Q2 report
November 03, 2023	Q3 report
OTHER EVENTS	

CEO: Jouni Heinonen CFO: Mikko Rummukainen IR: Sanna Ahvenniemi Mäkituvantie 5 01510 Vantaa Tel: +358 20 7541 200

### Chemicals/Finland, February 20, 2023 Company update

#### **DEFINITIONS**

extraord. items and taxes– income taxes + minority interest  Number of shares
ividend for the financial period per share
ash flow)
let financial items – Taxes – Increase in working apital – Cash NRIs ± Other adjustments
ow)
flow – operative CAPEX – acquisitions + divestments
Free cash flow  Market cap
/sales
expenditure – divestments – acquisitions Sales
ital
Current assets – current liabilities
I/Share
al assets – non-interest bearing debt Number of shares
Net debt Equity
Interest bearing debt ers' equity + minority interest + taxed provisions
s' equity + minority interest + taxed provisions Total assets – interest-free loans
annual growth rate = Average growth per year

Chemicals/Finland, February 20, 2023 Company update

#### Important Disclosures


Evli Research Partners Plc ("ERP") uses 12-month target prices. Target prices are defined by utilizing analytical techniques based on financial theory including (but not limited to) discounted cash flow analysis and comparative valuation. The selection of valuation methods depends on different circumstances. Target prices may be altered on the basis of new information coming to light in the underlying company or changes in interest rates, changes in foreign exchange rates, other securities prices or market indices or outlook for the aforementioned factors or other factors that may change the conditions of financial markets. Recommendations and changes by analysts are available at <u>Analysts' recommendations and ratings revisions</u>.

Investment recommendations are defined as follows:

Target price compared to share price Recommendation

< -10 % SELL -10 - (+10) % HOLD > 10 % BUY

ERP's investment recommendation of the analyzed company is updated at least 2 times per year.



The graph above shows the distribution of ERP's recommendations of companies under coverage in 11th of May 2020. If recommendation is not given, it is not mentioned here.

#### Name(s) of the analyst(s): Ilvonen

This research report has been prepared by Evli Research Partners Plc ("ERP" or "Evli Research"). ERP is a subsidiary of Evli Plc. Production of the investment recommendation has been concluded on [20.2.2023, 9:15]. This report has been published on [20.2.2023, 9:35].

None of the analysts contributing to this report, persons under their guardianship or corporations under their control have a position in the shares of the company or related securities.

The date and time for any price of financial instruments mentioned in the recommendation refer to the previous trading day's closing price(s) unless otherwise stated in the report.

Each analyst responsible for the content of this report assures that the expressed views accurately reflect the personal views of each analyst on the covered companies and securities. Each analyst assures that (s)he has not been, nor are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

Companies in the Evli Group, affiliates or staff of companies in the Evli Group, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report.

Neither ERP nor any company within the Evli Group have managed or co-managed a public offering of the company's securities during the last 12 months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the research report.

ERP has signed an agreement with the issuer of the financial instruments mentioned in the recommendation, which includes production of research reports. This assignment has a limited economic and financial impact on ERP and/or Evli. Under the assignment ERP performs services including, but not limited to, arranging investor meetings or –events, investor relations communication advisory and production of research material.

ERP or another company within the Evli Group does not have an agreement with the company to perform market making or liquidity providing services.

For the prevention and avoidance of conflicts of interests with respect to this report, there is an information barrier (Chinese wall) between Investment

#### **EVLI EQUITY RESEARCH**

### **EXEL COMPOSITES**

Chemicals/Finland, February 20, 2023 Company update

Research and Corporate Finance units concerning unpublished investment banking services to the company. The remuneration of the analyst(s) is not tied directly or indirectly to investment banking transactions or other services performed by Evli Plc or any company within Evli Group.

This report has not been disclosed to the company prior to its dissemination.

This report is provided and intended for informational purposes only and may not be used or considered under any circumstances as an offer to sell or buy any securities or as advice to trade any securities.

This report is based on sources ERP considers to be correct and reliable. The sources include information providers Reuters and Bloomberg, stock-exchange releases from the companies and other company news, Statistics Finland and articles in newspapers and magazines. However, ERP does not guarantee the materialization, correctness, accuracy or completeness of the information, opinions, estimates or forecasts expressed or implied in the report. In addition, circumstantial changes may have an influence on opinions and estimates presented in this report. The opinions and estimates presented are valid at the moment of their publication and they can be changed without a separate announcement. Neither ERP nor any company within the Evli Group are responsible for amending, correcting or updating any information, opinions or estimates contained in this report. Neither ERP nor any company within the Evli Group will compensate any direct or consequential loss caused by or derived from the use of the information represented in this publication.

All information published in this report is for the original recipient's private and internal use only. ERP reserves all rights to the report. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system of any nature, without the written permission of ERP.

This report or its copy may not be published or distributed in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa. The publication or distribution of this report in certain other jurisdictions may also be restricted by law. Persons into whose possession this report comes are required to inform themselves about and to observe any such restrictions.

Evli Plc is not registered as a broker-dealer with the U. S. Securities and Exchange Commission ("SEC"), and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Evli is not a member of the Financial Industry Regulatory Authority ("FINRA"). It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered in U.S. by Auerbach Grayson & Company, LLC (Auerbach Grayson) to Major U.S. Institutional Investors and is not available to, and should not be used by, any U.S. person or entity that is not a Major U.S. Institutional Investor. Auerbach Grayson is a broker-dealer registered with the U.S. Securities and Exchange Commission and is a member of the FINRA. U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Auerbach Grayson. The securities of non-U.S. issuers may not be registered with or subject to SEC reporting and other requirements.

ERP is not a supervised entity but its parent company Evli Plc is supervised by the Finnish Financial Supervision Authority.

Chemicals/Finland, February 20, 2023 Company update

## Contact information SALES, TRADING AND RESEARCH

Equity, ETF and Derivatives Sale	s	Trading	
Joachim Dannberg Ari Laine Kimmo Lilja	+358 9 4766 9123 +358 9 4766 9115 +358 9 4766 9130	Lauri Vehkaluoto (Head) Pasi Väisänen Antti Kässi Miika Ronkanen	+358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120
Structured Investments		Equity Research	
Heikki Savijoki Aki Lakkisto	+358 9 4766 9726 +358 9 4766 9123	Jonas Forslund Joonas Ilvonen Jerker Salokivi Teemu Reiman	+358 9 4766 9314 +358 44 430 9071 +358 9 4766 9149 +358 40 352 6175
Evli Investment Solutions			
Johannes Asuia	+358 9 4766 9205		



EVLI BANK PLC
Aleksanterinkatu 19 A
P.O. Box 1081
FIN-00101 Helsinki, FINLAND
Phone +358 9 476 690
Fax +358 9 634 382
Internet www.evli.com
E-mail firstname.lastname@evli.com

EVLI BANK PLC, STOCKHOLMSFILIAL Regeringsgatan 67 P.O. Box 16354 SE-103 26 Stockholm Sverige stockholm@evli.com Tel +46 (0)8 407 8000 Fax +46 (0)8 407 8001